Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study

Suguru Shirotake, Soichi Makino, Kenjiro Suzuki, Ryuichiro Araki, Takeo Kosaka, Koshiro Nishimoto, Masafumi Oyama, Shingo Kato

Research output: Contribution to journalArticle

Abstract

Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. : The 5- and 7-year overall survival rates were 97.9 and 91.1%. By PSA levels (PSA 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5%, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. : We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.

Original languageEnglish
Pages (from-to)87-91
Number of pages5
JournalJapanese Journal of Clinical Oncology
Volume49
Issue number1
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Brachytherapy
Prostatic Neoplasms
Radiotherapy
Retrospective Studies
Recurrence
Neoplasm Grading
Survival Rate
Neoadjuvant Therapy
Prostate-Specific Antigen
Androgens
Survival
Therapeutics

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer : a single institutional retrospective study. / Shirotake, Suguru; Makino, Soichi; Suzuki, Kenjiro; Araki, Ryuichiro; Kosaka, Takeo; Nishimoto, Koshiro; Oyama, Masafumi; Kato, Shingo.

In: Japanese Journal of Clinical Oncology, Vol. 49, No. 1, 01.01.2019, p. 87-91.

Research output: Contribution to journalArticle

Shirotake, Suguru ; Makino, Soichi ; Suzuki, Kenjiro ; Araki, Ryuichiro ; Kosaka, Takeo ; Nishimoto, Koshiro ; Oyama, Masafumi ; Kato, Shingo. / Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer : a single institutional retrospective study. In: Japanese Journal of Clinical Oncology. 2019 ; Vol. 49, No. 1. pp. 87-91.
@article{6a45373b60a24ec1929806d12842001f,
title = "Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer: a single institutional retrospective study",
abstract = "Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. : The 5- and 7-year overall survival rates were 97.9 and 91.1{\%}. By PSA levels (PSA 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5{\%}, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. : We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.",
author = "Suguru Shirotake and Soichi Makino and Kenjiro Suzuki and Ryuichiro Araki and Takeo Kosaka and Koshiro Nishimoto and Masafumi Oyama and Shingo Kato",
year = "2019",
month = "1",
day = "1",
doi = "10.1093/jjco/hyy174",
language = "English",
volume = "49",
pages = "87--91",
journal = "Japanese Journal of Clinical Oncology",
issn = "0368-2811",
publisher = "Oxford University Press",
number = "1",

}

TY - JOUR

T1 - Clinical outcome of high dose rate brachytherapy with external beam radiotherapy for high-risk prostate cancer

T2 - a single institutional retrospective study

AU - Shirotake, Suguru

AU - Makino, Soichi

AU - Suzuki, Kenjiro

AU - Araki, Ryuichiro

AU - Kosaka, Takeo

AU - Nishimoto, Koshiro

AU - Oyama, Masafumi

AU - Kato, Shingo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. : The 5- and 7-year overall survival rates were 97.9 and 91.1%. By PSA levels (PSA 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5%, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. : We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.

AB - Objectives: : This study investigated the clinical outcome of neoadjuvant androgen deprivation therapy followed by high dose rate brachytherapy (HDR-BT, called NEH) with external beam radiotherapy (EBRT) in high-risk prostate cancer (PCa) patients in our institution. : From 2007 to 2012, 192 high-risk PCa patients underwent neoadjuvant treatment-EBRT-NEH ( n = 192). Relations between clinical factors (prostate-specific antigen; PSA, cT stage, Gleason score) and biochemical recurrence were retrospectively analyzed. : The 5- and 7-year overall survival rates were 97.9 and 91.1%. By PSA levels (PSA 20 ng/ml, 20 ng/ml < PSA≤50 ng/ml and PSA > 50 ng/ml), 5-year biochemical recurrence-free survival rates were 85.7, 84.7 and 54.5%, respectively. There were no significant differences between biochemical recurrence and cT stage or Gleason score. : We found that NEH can contribute to better biochemical recurrence free survival of high-risk PCa patients with PSA below 50 ng/ml. High-risk PCa patients with PSA over 50 ng/ml may require more aggressive local or systemic treatment.

UR - http://www.scopus.com/inward/record.url?scp=85059498883&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059498883&partnerID=8YFLogxK

U2 - 10.1093/jjco/hyy174

DO - 10.1093/jjco/hyy174

M3 - Article

C2 - 30476164

AN - SCOPUS:85059498883

VL - 49

SP - 87

EP - 91

JO - Japanese Journal of Clinical Oncology

JF - Japanese Journal of Clinical Oncology

SN - 0368-2811

IS - 1

ER -